Glypvilo

Glypvilo is a prescription oral medication whose active ingredient is vildagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used in the management of type 2 diabetes mellitus. It is marketed in the European Union and is supplied as an oral dosage form, though specific strength information varies by country.

Glypvilo is indicated for adults with type 2 diabetes mellitus when diet, exercise, and other oral agents do not provide adequate glycaemic control. It may be used as monotherapy or in combination with other antidiabetic drugs.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin for enhanced effect. - May be added to sulfonylureas when additional control is needed. - Used alongside basal insulin in patients requiring insulin support. - Considered when patients have contraindications to other oral agents.

Side effects of Glypvilo vary in frequency and severity. Common reactions are usually mild and transient, while serious events are rare but require medical attention.

Common: - Upper respiratory tract infection symptoms. - Headache or mild dizziness. - Gastrointestinal discomfort such as nausea. - Mild skin rash or itching.

Serious: - Severe hypersensitivity reactions, including angio‑edema. - Pancreatitis presenting with abdominal pain. - Significant hepatic enzyme elevations. - Acute kidney injury in susceptible individuals. - Persistent hypoglycaemia when combined with insulin or sulfonylureas.

Before starting Glypvilo, certain health considerations should be reviewed to minimise risk.

- Assess renal function; dose adjustment may be needed in impairment. - Monitor liver enzymes periodically, especially in patients with hepatic disease. - Use caution in elderly patients due to increased sensitivity to side effects. - Evaluate for a history of pancreatitis before initiating therapy. - Discuss pregnancy and breastfeeding plans with a healthcare professional. - Review all concomitant medications to avoid potential interactions. - Advise patients to report any signs of severe skin reactions promptly.

Glypvilo can interact with several drug classes, influencing its efficacy or safety profile.

Avoid: - Strong CYP450 inhibitors that may increase vildagliptin plasma levels. - Concurrent use with other DPP‑4 inhibitors, which can lead to additive effects. - Medications known to cause pancreatitis, such as certain GLP‑1 receptor agonists.

Use with caution: - Sulfonylureas or insulin, as the risk of hypoglycaemia may rise. - Diuretics that affect renal clearance, requiring monitoring of renal function. - NSAIDs that may impact kidney function, especially in patients with pre‑existing renal disease. - Anticoagulants, where close monitoring of coagulation parameters is advisable.